PFE

Pfizer, Inc.

27.73 USD

Last updated Aug 20, 14:34 UTC

Yesterday HIGH

$28.44

Yesterday LOW

$27.58

52w HIGH

$28.74

52w LOW

$23.58

EPS

0.77

PE

36.01

Next Earnings

Nov 3, 2026

Overview News Unusual Options Flow Insider Transactions Government Trades Fundamentals

Pfizer, Inc. stock is up 11.19% since 30 days ago. The next earnings date is Nov 3, 2026. The company has had above-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 50% of the previous 49 August’s closed higher than July. In the last 10 Unusual Options Trades, there were 8 CALLs, 2 PUTs. 100% of analysts rate it a buy.

Options Flow Last 10
Date & Time	Expiration Date	Strike Price	Trade Type	Size	Open Interest

19 Aug 19:09	18 Sep, 2026	28.00	CALL	407	71464
19 Aug 19:27	21 Jan, 2028	30.00	PUT	62	7077
19 Aug 19:30	18 Sep, 2026	27.00	PUT	5200	6247
19 Aug 19:38	18 Sep, 2026	27.00	CALL	200	39489
19 Aug 19:55	15 Jan, 2027	30.00	CALL	500	61178
20 Aug 13:33	21 Aug, 2026	27.00	CALL	738	40009
20 Aug 13:50	18 Sep, 2026	26.00	CALL	231	36238
20 Aug 14:14	21 Jan, 2028	30.00	CALL	170	28746
20 Aug 14:17	21 Aug, 2026	27.00	CALL	407	40009
20 Aug 14:19	21 Aug, 2026	25.00	CALL	499	20071

Advanced Data Unlock

Benzinga Newsdesk

Tue Aug 4, 2026

Pfizer Q2 Adj. EPS $0.77 Beats $0.69 Estimate, Sales $15.034B Beat $14.412B Estimate

Pfizer (NYSE:PFE) reported quarterly earnings of $0.77 per share which beat the analyst consensus estimate of $0.69 by 11.59 percent. This is a 1.28 percent decrease over earnings of $0.78 per share from the same period
Benzinga Newsdesk

Tue Aug 4, 2026

Pfizer Affirms FY2026 Adj EPS Guidance of $2.80-$3.00 vs $2.95 Est; Raises FY2026 Sales Guidance from $59.500B-$62.500B to $60.500B-$62.500B vs $61.793B Est

Pfizer (NYSE:PFE) affirms FY2026 Adj EPS guidance from $2.80-$3.00 to $2.80-$3.00 vs $2.95 analyst estimate. Raises FY2026 sales outlook from $59.500 billion-$62.500 billion to $60.500 billion-$62.500 billion vs $61.793
Avi Kapoor

Tue Aug 4, 2026

Dow Closes at Record High, Nasdaq Surges 2%, but Fear & Greed Index Signals Investors Are Still Playing It Safe

Fear & Greed Index improves, Dow Jones hits record high, oil prices fall after Trump's Iran decision. CNH & Makemytrip stocks gain on earnings.
Avi Kapoor

Tue Aug 4, 2026

Caterpillar, Pfizer and 3 Stocks to Watch Heading Into Tuesday

Stocks to watch today: Caterpillar, Palantir, McDonald's, Snap, Pfizer. Positive Q2 earnings reported and upbeat sales guidance issued.
Avi Kapoor

Tue Aug 4, 2026

Pfizer Gears Up For Q2 Print; Here Are The Recent Forecast Changes From Wall Street's Most Accurate Analysts

Pfizer (PFE) will release Q2 earnings on Aug. 4, expected to report lower EPS of 68 cents and revenue at $14.39B. Stock rose 0.1% on Monday.
Kaustubh Bagalkote

Mon Aug 3, 2026

SpaceX Could Swing $204 Billion After Earnings

Earnings set for tight window on Tuesday, Benzinga Pro data show options pricing 3.19% move for Pfizer and 5.15% for Amgen and Gilead Sciences.
Vandana Singh

Mon Aug 3, 2026

AstraZeneca-Bristol Myers Merger Buzz Puts Patent Expiration and Deal Economics in Focus

AstraZeneca and Bristol Myers reportedly discuss a $400 billion merger as analyst assesses valuation, patent risks and regulatory hurdles.
Vandana Singh

Thu Jul 30, 2026

Pfizer Prepares Global Regulatory Litfulo Filings Following Skin Pigment Improvements In Late-Stage Trials

Pfizer reports Phase 3 data for LITFULO in treating nonsegmental vitiligo and plans to submit global regulatory filings.
Benzinga Newsdesk

Thu Jul 30, 2026

Pfizer Announces Topline Results From Two Phase 3 Trials Of LITFULO In Patients With Vitiligo; Both The 50 And 100 Milligram Doses Delivered Significant, Clinically Meaningful Improvements Over Placebo

Phase 3 trials evaluated the efficacy and safety of LITFULO once daily in patients with both active and stable nonsegmental vitiligo (NSV) and who had a broad range of disease severity. The TRANQUILLO study included
Benzinga Newsdesk

Wed Jul 29, 2026

European Commission Grants Marketing Authorization For Pfizer And BioNTech's 2026-27 COVID-19 Vaccine Formula

The formula targets the XFG variant, for active immunization to prevent COVID-19 caused by SARS-CoV-2 in individuals 6 months of age and older. The adaptation is based on the recommendation from the Emergency Task Force

Guggenheim

Fri Aug 7, 19:01

buy

confirm

Advanced Data Unlock

Albert Bourla, Chairman & CEO

Fri Aug 14, 2026

PFE Recent Insider Trades and Stock Chart

22 shares awarded
Albert Bourla, Chairman & CEO

Wed Aug 12, 2026

PFE Recent Insider Trades and Stock Chart

38,000 shares bought
Jennifer B Damico, SVP & Controller

Wed Aug 5, 2026

PFE Recent Insider Trades and Stock Chart

3,278 shares sold
Ronald E Blaylock, Director

Wed Aug 5, 2026

PFE Recent Insider Trades and Stock Chart

39,231 shares bought
Mortimer J Buckley, Director

Wed Aug 5, 2026

PFE Recent Insider Trades and Stock Chart

37,632 shares bought
Albert Bourla, Chairman & CEO

Fri Jul 31, 2026

PFE Recent Insider Trades and Stock Chart

24 shares awarded